Comparison of tissue, plasma ctDNA and bile cfDNA as specimen sources in CCA.
| Comparison criterion | Tissue | Plasma ctDNA | Bile cfDNA |
|---|---|---|---|
| Primary role | Histological diagnosis, grading, immunohistochemistry, baseline NGS | Longitudinal monitoring, MRD detection, recurrence surveillance | Local molecular characterisation, diagnosis of indeterminate biliary strictures |
| Invasiveness | Invasive (biopsy, brushing, surgery) | Minimally invasive (venepuncture) | Procedurally invasive (ERCP, PTBD, surgery) |
| Repeatability | Limited; tissue exhaustion is a real concern | High; suitable for serial sampling | Low; requires biliary access at each time point |
| Tumour fraction | High when cellularity is adequate; low in desmoplastic/necrotic samples | Variable; low in early/localised disease | Higher than plasma in biliary malignancies; enriched in long DNA fragments |
| Spatial heterogeneity | Limited; single biopsy may miss intratumoural heterogeneity | May capture systemic heterogeneity in advanced disease | May capture heterogeneity along biliary tree; affected by sampling site vs tumour location |
| Fusion detection | Good with RNA-based or hybrid-capture NGS | Moderate; dependent on assay design and ctDNA fraction | Potentially limited; RNA stability and extraction reproducibility in bile are less established, and fusion detection depends on assay design and input quality |
| Current evidence | Standard of care; required for histological diagnosis and molecular profiling [1–3] | Strongest evidence for postoperative MRD and recurrence monitoring [37, 38] | Most mature for indeterminate biliary strictures [9] and PSC surveillance [19, 20] |
| When preferred | Whenever adequate material is available; required for histological diagnosis | Serial monitoring after surgery; when tissue is unavailable and rapid results are needed | When biliary access is already indicated and tissue is insufficient or plasma is uninformative |
| Key limitations | Inadequate cellularity (CCA); DNA exhaustion; fails to capture tumour evolution over time | Low ctDNA fraction in early/localised disease; reduced sensitivity for fusions and CNVs | Requires invasive procedure; affected by cholangitis, stents, sampling site; not suitable for serial monitoring |
cfDNA: cell-free DNA; CNV: copy number variation; ctDNA: circulating tumour DNA; ERCP: endoscopic retrograde cholangiopancreatography; MRD: minimal residual disease; NGS: next-generation sequencing; PSC: primary sclerosing cholangitis; PTBD: percutaneous transhepatic biliary drainage.